Stryker (SYK) Cash from Financing Activities (2009 - 2026)
Stryker (SYK) posted quarterly Cash from Financing Activities of -$95.0 million for Q2 2026, up 90.39% year-over-year from -$49.9 million in Q2 2025, and up 93.71% on a QoQ basis from -$1.5 billion in Q1 2026.
Stryker (SYK) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Stryker has reported Cash from Financing Activities for 18 years, with the latest figure at -$95.0 million in Q2 2026.
- Cash from Financing Activities for Q2 2026 came in at -$95.0 million, up 90.39% year-over-year; the trailing twelve-month figure through Jun 2026 was -$3.0 billion (down 226.33% YoY), and the FY2025 annual result was $113.0 million, up 121.52% from the prior year.
- Cash from Financing Activities improved to -$95.0 million in Q2 2026, from -$1.5 billion in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $2.7 billion in Q3 2024 and troughed at -$1.8 billion in Q4 2024.
- A 5-year average of -$242.2 million and a median of -$434.0 million in 2022 frame the typical range for Cash from Financing Activities.
- The largest YoY upside for Cash from Financing Activities was 728.67% in 2024 against a maximum downside of 527.27% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$446.0 million in 2022, then jumped by 35.87% to -$286.0 million in 2023, then plunged by 527.27% to -$1.8 billion in 2024, then jumped by 39.07% to -$1.1 billion in 2025, then surged by 91.31% to -$95.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$95.0 million in Q2 2026, -$1.5 billion in Q1 2026, and -$1.1 billion in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Zimmer Biomet Holdings | 19.21 Bn | 18.80 Bn | 1.54 Bn | -271.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.00 Mn |
| Jun 30, 2026 | -95.00 Mn |
| Mar 31, 2026 | -1.51 Bn |
| Mar 31, 2026 | -1.51 Bn |
| Dec 31, 2025 | -1.09 Bn |
| Dec 31, 2025 | -1.09 Bn |
| Sep 30, 2025 | -339.00 Mn |
| Sep 30, 2025 | -339.00 Mn |
| Jun 30, 2025 | -989.00 Mn |
| Jun 30, 2025 | -989.00 Mn |
| Mar 31, 2025 | 2.53 Bn |
| Mar 31, 2025 | 2.53 Bn |
| Dec 31, 2024 | -1.79 Bn |
| Dec 31, 2024 | -1.79 Bn |
| Sep 30, 2024 | 2.65 Bn |
| Sep 30, 2024 | 2.65 Bn |
| Jun 30, 2024 | -966.00 Mn |
| Jun 30, 2024 | -966.00 Mn |
| Mar 31, 2024 | -418.00 Mn |
| Mar 31, 2024 | -418.00 Mn |